Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis. 1986

E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves

Topical clobetasol propionate or vehicle ointment was applied daily for 3 days to psoriatic plaques on eight patients. Skin chamber exudates from untreated, steroid and vehicle treated lesions were assayed for arachidonic acid (AA), leukotriene B4 (LTB4), prostaglandin E2 (PGE2) and 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) before, and at 24 h and 72 h after treatment. Significant reductions in AA and LTB4 were observed at 72 h in steroid treated lesions. The reduction in 12-HETE levels observed after steroid treatment was not statistically significant. PGE2 levels in lesional psoriatic skin were unaltered. The reduction of AA, and LTB4 was associated with clinical improvement of psoriasis.

UI MeSH Term Description Entries
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D002990 Clobetasol A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression. Clobetasol 17-Propionate,Clobetasol Propionate,Clobex,Clofenazon,Cormax,Dermovate,Embeline,Embeline E,OLUX,Temovate,Clobetasol 17 Propionate
D005122 Exudates and Transudates Exudates are fluids, CELLS, or other cellular substances that are slowly discharged from BLOOD VESSELS usually from inflamed tissues. Transudates are fluids that pass through a membrane or squeeze through tissue or into the EXTRACELLULAR SPACE of TISSUES. Transudates are thin and watery and contain few cells or PROTEINS. Transudates,Exudates,Transudates and Exudates,Exudate,Transudate
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006893 Hydroxyeicosatetraenoic Acids Eicosatetraenoic acids substituted in any position by one or more hydroxy groups. They are important intermediates in a series of biosynthetic processes leading from arachidonic acid to a number of biologically active compounds such as prostaglandins, thromboxanes, and leukotrienes. HETE,Acids, Hydroxyeicosatetraenoic

Related Publications

E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
January 1983, Annals of the New York Academy of Sciences,
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
May 1999, The Journal of pharmacy and pharmacology,
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
October 1982, Lancet (London, England),
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
July 1984, The Journal of investigative dermatology,
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
November 1987, British journal of pharmacology,
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
January 1998, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes,
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
April 2008, Journal of applied physiology (Bethesda, Md. : 1985),
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
February 1988, Agents and actions,
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
April 1987, The British journal of dermatology,
E Wong, and R M Barr, and F M Cunningham, and K Mistry, and P M Woollard, and A I Mallet, and M W Greaves
August 1997, Biochemical and biophysical research communications,
Copied contents to your clipboard!